DOCSLIB.ORG

Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients with COPD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients with COPD Dransfield MT1, Halpin DMG2, Han MK3, Hartley B4, Jones CE5, Kalhan R6, Kilbride S7, Time-dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Kunisaki KM8, Lange P9,10, Lipson DA5,11, Martinez FJ12, Singh D13, Wise RA14 1Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA; 2University of Exeter Medical School, University of Exeter, Exeter, UK; 3Univeristy of Michigan, Ann Arbor, MI, USA; 4Veramed Ltd, Twickenham, UK; 5GSK, Collegeville, PA, USA; 6Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 7GSK, Stockley Park West, Uxbridge, COPD: Post Hoc Analysis From the IMPACT Trial Middlesex, UK; 8Minneapolis Veterans Affairs Health Care System, University of Minnesota Twin Cities Medical School, Minneapolis, MN, USA; 9University of Copenhagen, Copenhagen, Denmark; 10Herlev-Gentofte Hospital, Herlev, Denmark; 11Perelman School of Medicine, University of Pennsylvania, PA, USA; 12New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA; 13The University of Manchester, Poster No. P1458 Manchester University NHS Foundation Trust, UK; 14Johns Hopkins University School of Medicine, Baltimore, MD, USA Introduction Results ● Patients with chronic obstructive pulmonary disease (COPD) and ● A total of 10,355 patients were included in the intent-to-treat population ● A significantly increased risk of a CVAESI or CVAESI resulting in cardiovascular disease (CVD), or risk factors for CVD, have been shown to be Figure 3. Risk of a first CVAESI during or following a moderate or severe (Table 1). hospitalization or death was seen during a moderate or severe exacerbation exacerbation event by CV risk factors at screening at increased risk of subsequent cardiovascular (CV) events following an event, which decreased over time thereafter (Figure 1). exacerbation, particularly those patients requiring hospitalization for their ● Overall, the number of patients experiencing a CV event during or following exacerbation and within the first 30 days after an exacerbation.1 an exacerbation was low (Table 2). – The increase in the risk of a CVAESI or CVAESI resulting in hospitalization 0 CV risk factors 1 CV risk factor ≥2 CV risk factors or death was higher during a severe exacerbation (hazard ratio: 21.84 and ● The Phase 3 IMPACT trial assessed single-inhaler triple therapy with Moderate exacerbation Severe exacerbation Table 1. Baseline characteristics2,3 41.29, respectively) than during a moderate exacerbation (hazard ratio: 100 100 fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI or 2.63 and 2.46, respectively). *** *** *** UMEC/VI in patients with symptomatic COPD at risk of exacerbations and Total scale) (N=10,355) 10 with varying degrees of CVD or CV risk.2,3 This post hoc analysis evaluated Figure 1. Risk of a first CVAESI or CVAESI resulting in hospitalization or 10 10 the time-dependent risk of CV events following an exacerbation in patients Age, mean (SD) years 65.3 (8.3) death during or following a moderate or severe exacerbation event *** *** *** with COPD who participated in the IMPACT trial. ** ** Male, n (%) 6870 (66) CVAESI CVAESI resulting in hospitalization or death BMI, mean (SD) kg/m2 26.6 (6.1) 100 Moderate exacerbation 100 Severe exacerbation 1 1 Methods *** Former smokers, n (%) 6768 (65) scale) *** 10 Annual rate of moderate or ratio (95% CI) Hazard (log Exacerbation history in prior 12 months, n (%) 10 10 *** 0.1 0.1 severe exacerbations Exacerbation 1–30 31–90 91–365 Exacerbation 1–30 31–90 91–365 Randomized Double blind Multicenter *** event days days days event days days days <2 moderate and no severe exacerbations 3056 (30) *** *** Moderate exacerbation: *** Study any exacerbation requiring antibiotics ≥2 moderate or ≥1 severe exacerbation 7299 (70) Phase 3 1 and/or oral/systemic corticosteroids 1 *p<0.05; **p<0.01; ***p<0.001 vs baseline period. Note: no events were recorded within 91–365 days post severe (CTT116855 [NCT02164513]) exacerbation in the 1 CV risk factor subgroup. Postbronchodilator FEV1 % predicted, mean (SD) 45.5 (14.8) Severe exacerbation: Primaryendpoint any exacerbation leading to CAT score, mean (SD) 20.1 (6.1) ≥40 years of age hospitalization or death ratio CI) (95% (log Hazard 0.1 0.1 Exacerbation 1–30 31–90 91–365 Exacerbation 1–30 31–90 91–365 Symptomatic COPD: CV risk factors, n (%)* event days days days event days days days CAT score ≥10 at screening Risk (time-to-first) CVAESI* or 0 3343 (32) CVAESI resulting in hospitalization ***p<0.001 vs baseline period. CI, confidence interval. FEV <50% predicted at screening 1 2885 (28) 1 or death: Conclusions and ≥1 moderate/severe ≥2 4127 (40) exacerbation in prior 12 months During a moderate or ● A similar trend was seen in the subgroup analyses, with similar increases *As captured in the electronic case report form; CV risk factors included: angina pectoris; coronary artery disease; ● In IMPACT, while the overall number of patients experiencing CV Patients severe exacerbation event myocardial infarction; arrhythmia; congestive heart failure; hypertension; cerebrovascular accident; carotid or in risk of CVAESI regardless of patients exacerbation history (Figure 2) and OR and events during or following an exacerbation was low, a aorto-femoral vascular disease; diabetes mellitus; hypercholesterolemia. BMI, body mass index; SD, standard CV risk factors at screening (Figure 3). 1–30 days deviation. significantly increased risk of CVAESI or CVAESI resulting in FEV1 50—80% at screening 31–90 days and ≥2 moderate or ≥1 severe 91–365 days hospitalization or death was seen during a moderate or severe exacerbation in prior 12 months Figure 2. Risk of a first CVAESI during or following a moderate or severe following a moderate or Table 2. Number of patients experiencing first CV events during or exacerbation, with the risk decreasing over time thereafter. severe exacerbation event exacerbation event by exacerbation history following exacerbation events – This increased risk was higher during a severe exacerbation CVAESI resulting in <2 moderate and 0 severe exacerbations ≥2 moderate or ≥1 severe exacerbation compared with a moderate exacerbation regardless of • Analyzed using a time-dependent Event CVAESI Fluticasone furoate 100 mcg hospitalization or death FF/UMEC/VI repeated measures Cox model 100 Moderate exacerbation 100 Severe exacerbation CVAESI severity. Umeclidinium 62.5 mcg Once daily Patients Patients *** Vilanterol 25 mcg • Hazard for a CV event was *** compared between the period experiencing experiencing scale) ● A similar increase in risk was observed regardless of the before and after an exacerbation Total n CV event, n (%) Total n CV event, n (%) 10 10 10 presence of CV risk factors at screening or the patients’ *** ** Post hoc Posthoc analysis *** * FF/VI Fluticasone furoate 100 mcg • For exacerbation and CV events Moderate exacerbations *** exacerbation history, with the risk increase following a similar Once daily Vilanterol 25 mcg starting on the same day, the Exacerbation event 4207 80 (1.9) 4361 19 (0.4) analysis was conducted as though 1 1 pattern as in the overall analysis. the exacerbation occurred first 1–30 days post event 3874 74 (1.9) 4050 26 (0.6) ● This analysis confirms the increased risk of CVAESI during and 31–90 days post event 3410 49 (1.4) 3599 22 (0.6) Treatments in the first 30 days following an exacerbation seen in other UMEC/VI Umeclidinium 62.5 mcg 0.1 0.1 Subgroup analyses conducted for: 91–365 days post event 2548 61 (2.4) 2710 18 (0.7) Once daily Vilanterol 25 mcg studies, highlighting a need for exacerbation prevention and • Exacerbation history in the past Severe exacerbations close patient monitoring following exacerbation events, 12 months (<2 moderate and 0 severe; ratio CI) (95% (log Hazard 0.01 0.01 ≥2 moderate or ≥1 severe) Exacerbation event 1099 124 (11.3) 1160 64 (5.5) Exacerbation 1–30 31–90 91–365 Exacerbation 1–30 31–90 91–365 irrespective of a patient’s exacerbation history or CV risk factors. event days days days event days days days 52 weeks • CV risk factors at screening (0, 1, ≥2) 1–30 days post event 790 12 (1.5) 873 9 (1.0) 31–90 days post event 600 13 (2.2) 667 2 (0.3) *p<0.05; **p<0.01; ***p<0.001 vs baseline period. Note: no events were recorded within 1–30 days post severe *CVAESI included cardiac arrhythmia, cardiac failure, central nervous system hemorrhages, and cerebrovascular 91–365 days post event 386 10 (2.6) 435 6 (1.4) exacerbation in the <2 moderate and 0 severe exacerbations subgroup. conditions, hypertension, and ischemic heart disease. CAT, COPD Assessment Test; CVAESI, cardiovascular adverse event of special interest; FEV1, forced expiratory volume in 1 second. financial support from the American College of Chest Physicians, AstraZeneca, Boehringer Ingelheim, Continuing Education, ConCert, Genentech, GSK, Inova Disclosures Fairfax Health System, Miller Communications, National Society for Continuing Education, Novartis, Pearl Pharmaceuticals, PeerView Communications, Prime Acknowledgments References Communications, Puerto Rico Respiratory Society, Chiesi, Roche, Sunovion, Theravance, Potomac, University of Alabama Birmingham, Physicians Education ● This study was funded by GlaxoSmithKline (GSK; study number CTT116855; NCT02164513). ELLIPTA is owned by or licensed to the GSK Group of ● Editorial support (in the form of writing assistance, including development of the initial draft 1. Kunisaki KM, et al. Am J Resp Crit Care Med 2018;198(1):51–7. Companies. Resource, Canadian Respiratory Network and Teva, non-financial support from ProterrixBio, Gilead, Nitto, and Zambon, and personal fees from Columbia based on author direction, assembling tables and figures, collating authors’ comments, University, Integritas, MD Magazine, Methodist Hospital Brooklyn, New York University, Unity, UpToDate, WedMD/MedScape, Western Connecticut Health ● On behalf of all authors, an audio recording of this poster was prepared by Mark Dransfield, who did not receive any payment for this recording.
Load more

Recommended publications
  • Jefferies 2013 Global Healthcare Conference in London
    Jefferies 2013 Global Healthcare Conference in London At the 2012 Jefferies Global Healthcare Conference, there were well over 200 healthcare companies participating with a combined market cap of $1 trillion and close to 1,300 one-on-one/small group meetings over the two-day event. The 2013 conference is set to follow the same footsteps, featuring public and private leading INVITATION global healthcare companies within the areas of pharmaceuticals, biotech, generics, 20-21 NOVEMBER 2013 medtech and healthcare services from the US, Central and Eastern Europe, Latin The Waldorf Hilton America, India, China, Japan, Egypt, Israel and Russia. London, UK Throughout the two-day event, we will feature concurrent tracks of informative presentations as well as 1x1/small group meetings, and thematic panel discussions. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative. © 2013 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM Clinigen Group Plc Ion Beam Applications Active Biotech AB Syneron Medical Ltd. Specialty Pharma & Healthcare Services Medical Products Biotechnology Medical Technology Paul Thomas; CTO Olivier Legrain, CEO Tomas Leanderson; President and CEO Hugo Goldman, CFO 8:40 AM Valneva Celltrion, Inc.
    [Show full text]
  • Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
    Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT
    [Show full text]
  • Misinterpretation of Time-To-First Event Curves Can Lead to Inappropriate Treatment
    AGORA | CORRESPONDENCE Misinterpretation of time-to-first event curves can lead to inappropriate treatment To the Editor: Great care should be taken when assessing the consistency of treatment effect over time based on a survival curve plot, and even more so when a treatment affects a repeating event end-point, such as exacerbations, rather than an event that can occur only once, like death. In their recent editorial in the European Respiratory Journal,SUISSA and ARIEL [1] make the assertation that survival functions plotted from Kaplan–Meier estimates from figure 1b in the IMPACT study [2] “clearly show that the difference in the rate of exacerbation between LAMA/LABA/ICS and LAMA/LABA over follow-up is due to the first month’s surge, with practically no differences in the subsequent rates between the two groups”. However, this statement is based on a misunderstanding of the survival analyses presented. The events plotted on the figure are the first moderate or severe COPD exacerbations experienced by a patient in the IMPACT study. The statements made by SUISSA and ARIEL [1] about exacerbation rates refer to the rate of first exacerbations only, and not to the rate of all exacerbations during the study. Their conclusion that the rates of first exacerbations, and ratio between those rates changes over time is correct. However, this is entirely in line with statistical theory for repeated events with overall constant rates. It cannot be used to support any conclusion that the difference in the rate of exacerbation is due to a “first month’s surge”. The “digitised” curve of first events behaves entirely consistently with constant rate events.
    [Show full text]
  • International Smallcap Separate Account As of July 31, 2017
    International SmallCap Separate Account As of July 31, 2017 SCHEDULE OF INVESTMENTS MARKET % OF SECURITY SHARES VALUE ASSETS AUSTRALIA INVESTA OFFICE FUND 2,473,742 $ 8,969,266 0.47% DOWNER EDI LTD 1,537,965 $ 7,812,219 0.41% ALUMINA LTD 4,980,762 $ 7,549,549 0.39% BLUESCOPE STEEL LTD 677,708 $ 7,124,620 0.37% SEVEN GROUP HOLDINGS LTD 681,258 $ 6,506,423 0.34% NORTHERN STAR RESOURCES LTD 995,867 $ 3,520,779 0.18% DOWNER EDI LTD 119,088 $ 604,917 0.03% TABCORP HOLDINGS LTD 162,980 $ 543,462 0.03% CENTAMIN EGYPT LTD 240,680 $ 527,481 0.03% ORORA LTD 234,345 $ 516,380 0.03% ANSELL LTD 28,800 $ 504,978 0.03% ILUKA RESOURCES LTD 67,000 $ 482,693 0.03% NIB HOLDINGS LTD 99,941 $ 458,176 0.02% JB HI-FI LTD 21,914 $ 454,940 0.02% SPARK INFRASTRUCTURE GROUP 214,049 $ 427,642 0.02% SIMS METAL MANAGEMENT LTD 33,123 $ 410,590 0.02% DULUXGROUP LTD 77,229 $ 406,376 0.02% PRIMARY HEALTH CARE LTD 148,843 $ 402,474 0.02% METCASH LTD 191,136 $ 399,917 0.02% IOOF HOLDINGS LTD 48,732 $ 390,666 0.02% OZ MINERALS LTD 57,242 $ 381,763 0.02% WORLEYPARSON LTD 39,819 $ 375,028 0.02% LINK ADMINISTRATION HOLDINGS 60,870 $ 374,480 0.02% CARSALES.COM AU LTD 37,481 $ 369,611 0.02% ADELAIDE BRIGHTON LTD 80,460 $ 361,322 0.02% IRESS LIMITED 33,454 $ 344,683 0.02% QUBE HOLDINGS LTD 152,619 $ 323,777 0.02% GRAINCORP LTD 45,577 $ 317,565 0.02% Not FDIC or NCUA Insured PQ 1041 May Lose Value, Not a Deposit, No Bank or Credit Union Guarantee 07-17 Not Insured by any Federal Government Agency Informational data only.
    [Show full text]
  • Jefferies 2014 Global Healthcare Conference in London
    Jefferies 2014 Global Healthcare Conference in London You are invited to attend the Jefferies Global Healthcare Conference on 19-20 November, 2014, at the Waldorf Hilton in London. Now in its fifth year, ours is the largest healthcare-dedicated conference in Europe. Last year, we had 230 participating healthcare companies with a combined market capitalisation of over INVITATION $1 trillion and close to 2,250 1x1/small-group meetings. The 2014 conference is set to follow 19-20 NOVEMBER 2014 in the same footsteps, featuring leading public and private companies from areas of The Waldorf Hilton pharmaceuticals, biotechnology, generics, consumer health, animal health, medical London, UK technology and healthcare services from the United States, Western and Emerging Europe, Middle East & Africa, Latin America, Russia, India, Israel, China, and Japan. This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative © 2014 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, NOVEMBER 19, 2014 Jefferies 2014 Global Healthcare Conference in London TRACK 1 TRACK 2 TRACK 3 TRACK 4 TRACK 5 ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM ALDWYCH 7:30 AM Breakfast and Registration 8:00 AM EMIS Group PLC( AIM:EMIS) Auris Medical Holding AG Sartorius AG (DB:SRT) Medivation, Inc.(NasdaqGS:MDVN) Ethypharm SA (Private) Healthcare Technology (NasdaqGM:EARS) Medical Products & Devices Biotechnology Pharmaceuticals Chris Spencer, CEO Pharmaceuticals Joerg Pfirrmann, CFO David Hung, M.D., President and CEO Hugues Lecat, CEO and Chairman of the Dr.
    [Show full text]
  • BTG Plc Annual Report Annual Plc BTG and Accounts 2014 Imagine Where We Can Go
    BTG plc Annual Report and Accounts 2014 BTG plc Annual Report and Accounts 2014 Imagine where we can go. Introduction BTG is a growing international specialist healthcare company. We develop innovative products in specialist areas of medicine where current treatment options are limited. Our products advance the treatment of people with liver cancer, blood clots and varicose veins, and of people who need antidotes if they are overexposed to certain medications or toxins. Inspired by patient need, we are investing to expand our portfolio with products that address today’s healthcare challenges. Partnership and innovation are at the heart of our approach. By delivering products that improve patient treatment, and that are valued by clinicians and payers, we will grow our business sustainably and will deliver significant value to all our stakeholders. Imagine where we can go. Find out more online www.btgplc.com Strategic report Our performance 02 An overview of our performance Group overview 04 this year, our business model, Chairman’s statement 06 our objectives and the principal risks Chief Executive’s review 08 we face, accompanied by relevant Our objectives 10 performance and operating information. Focus on Interventional Medicine: Vascular 14 Focus on Interventional Medicine: Oncology 16 Our business model 18 Read more page 03 Corporate citizenship 22 Market overview 24 Financial review 26 Risk management and principal risks 30 Governance Board of Directors 36 The Board of Directors and our Corporate governance report 38 approach to corporate governance Audit Committee report 46 and remuneration. Nomination Committee report 50 Directors’ remuneration report 51 Directors’ report 69 Statement of directors’ responsibilities 71 Read more page 35 Independent auditor’s report 72 Strategic report Strategic report Financials Consolidated income statement 76 Financial statements, notes Consolidated statement of comprehensive income 77 and other key data.
    [Show full text]
  • How Does Health Connect Us All?
    How does health connect us all? AstraZeneca Annual Report and Form 20-F Information 2010 Financial highlights $33.3bn Sales unchanged at $33,269 million ($32,804 million in 2009) $13.6bn Core operating profit unchanged at $13,603 million ($13,621 million in 2009) $6.71 Core EPS for the full year increased by 5% to $6.71 ($6.32 in 2009) $2.1bn Net share repurchases totalled $2,110 million ($nil in 2009) Important information for readers of this Annual Report and Form 20-F Information Statements of competitive position, growth rates and sales In this Annual Report, except as otherwise stated, market information regarding the position Cautionary statement regarding forward-looking statements of our business or products relative to its or their competition is based upon published The purpose of this Annual Report is to provide information to the members of the Company. statistical sales data for the 12 months ended 30 September 2010 obtained from IMS Health, The Company and its Directors, employees, agents and advisors do not accept or assume a leading supplier of statistical data to the pharmaceutical industry. For the US, dispensed responsibility to any other person to whom this Annual Report is shown or into whose hands new or total prescription data and audited sales data are taken, respectively, from IMS Health it may come and any such responsibility or liability is expressly disclaimed. In order, among National Prescription Audit and IMS National Sales Perspectives for the 12 months ended other things, to utilise the ‘safe harbour’ provisions of the US Private Securities Litigation 31 December 2010; such data is not adjusted for Medicaid and similar state rebates.
    [Show full text]
  • Aqua Bounty Technologies ABTX Pharmaceuticals & Biotechnology — USD 0.125 at Close 19 November 2015
    FTSE COMPANY REPORT Share price analysis relative to sector and index performance Data as at: 19 November 2015 Aqua Bounty Technologies ABTX Pharmaceuticals & Biotechnology — USD 0.125 at close 19 November 2015 Absolute Relative to FTSE UK All-Share Sector Relative to FTSE UK All-Share Index PERFORMANCE 19-Nov-2015 19-Nov-2015 19-Nov-2015 0.18 120 120 1D WTD MTD YTD Absolute 0.0 0.0 0.0 -26.5 0.17 110 110 Rel.Sector -0.3 -4.9 0.3 -25.6 Rel.Market -0.7 -3.0 0.4 -25.2 0.16 100 100 VALUATION (local currency) (local 0.15 90 90 Trailing Relative Price Relative Price 0.14 80 80 PE -ve Absolute Price Price Absolute EV/EBITDA -ve 0.13 70 70 PCF -ve PB 8.7 0.12 60 60 Price/Sales - Nov-2014 Feb-2015 May-2015 Aug-2015 Nov-2015 Nov-2014 Feb-2015 May-2015 Aug-2015 Nov-2015 Nov-2014 Feb-2015 May-2015 Aug-2015 Nov-2015 Div Yield 0.0 Absolute Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Div Payout 0.0 100 90 100 ROE -ve 90 80 90 Net Debt/Equity 0.7 80 70 80 70 70 60 60 60 DESCRIPTION 50 50 50 40 The Company engages in research, develop and 40 40 RSI (Absolute) RSI 30 commercialize products that improve aquaculture 30 30 productivity. The Company focuses on improving 20 20 20 productivity in the aquaculture market 10 10 10 RSI (Relative to FTSE UK All-Share Index) UK All-Share to FTSE (Relative RSI RSI (Relative to FTSE UK All-Share Sector) UK All-Share to FTSE (Relative RSI 0 0 0 Nov-2014 Feb-2015 May-2015 Aug-2015 Nov-2015 Nov-2014 Feb-2015 May-2015 Aug-2015 Nov-2015 Nov-2014 Feb-2015 May-2015 Aug-2015 Nov-2015 See final page and http://www.londonstockexchange.com/prices-and-markets/stocks/services-stock/ftse-note.htm for further details.
    [Show full text]
  • 2018 SIR Annual Scientific Meeting Faculty Financial Disclosures
    2018 SIR Annual Scientific Meeting Faculty Financial Disclosures Mohamed H.K. Abdelmaksoud Other: Proctor; Consultant: SIRTEX, Merit Medical Inc.; Advisory committee or review panel member: Merit medical Inc. J. Fritz Angle Consultant: Proteon, Dahchi Sankyo; Research grant recipient: Siemens Medical Hussein Aoun Consultant: BTG Medical Yasuaki Arai Royalties: Piolax Medical Devices, Sumitomo Bakelite Co., Ltd; Research grant recipient: Terumo Corporation,Toshiba Medical Systems, Taiho Pharmaceutical, Eisai Co., Ltd.; Advisory committee or review panel member: Eisai Inc; Speaking and teaching: Merit Medical Systems, Fuji Pharma Co., Ltd. ,Terumo International Systems, Nippon Kayaku, Toshiba Medical Systems, Bristol Meyer Squibb, Sumitomo Bakelite Co., Ltd., Bayer Pharmaceuticals, Boston Scientific Japan, Taiho Pharmaceutical, Guerbet Japan, Guerbet Asia Pacific Aravind Arepally Intellectual property rights: Surefire Medical; Consultant: SirTex Medical Bulent Arslan Advisory committee or review panel member: Medtronic; Speaking and teaching: Medtronic, Boston Scientific, Cook, Penumbra Jung Hwan Baek Consultant: STARmed (2017-2018), RF medical (2017 only) Sandeep Bagla Consultant: Medtronic, Boston Scientific, Teleflex, Terumo, Merit; Research grant recipient: Medtronic, Boston Scientific, Terumo, BTG, Renovo Giacomo Basadonna Board membership: Alira Health Douglas Beall Consultant: Benvenue, Lilly, Amendia, Medtronic; Speaking and teaching: Benvenue, Lilly, Medtronic; Board membership: SIR, Vexim, Lilly, Amendia, Medtronic; Ownership
    [Show full text]
  • UK's Global Bioscience Cluster 2016 the UK Bioindustry Association: Delivering the Best Possible Environment for Biotechnology Growth and Innovation
    Building something great: UK's Global Bioscience Cluster 2016 The UK BioIndustry Association: Delivering the best possible environment for biotechnology growth and innovation. We advocate to government at both the UK and European levels to improve policies, funding and taxation. We also work to improve the business environment by engaging with regulators, the City, venture capitalists, charities and patient groups. Join now: 320 members, 135 companies represented on Advisory Committees Save: Our members saved over £5.8M in 2016 through our Business Solutions programme Connect: Network and build relationships with 2,500+ industry leaders at our UK-wide events Influence: Be at the heart of policy development. Shape our sector and represent positive change for UK biotech Join UK’s trade association for biotechnology now: www.bioindustry.org/membership Contents Foreword from UK BioIndustry Association Chief Executive, Steve Bates, OBE 4 Foreword from Informa Pharma Executive Editor, John Hodgson 5 Overall trends for UK biotech in 2016 7 Venture capital funding 9 The UK venture capital picture has matured 9 Top UK venture capital rounds 2016 11 Venture capital raised – rest of Europe and USA 14 Public markets 16 UK IPOs 2016 16 Changes in global public markets for UK biotech 19 AIM persists as a source of follow-on finance, even when markets are more closed 21 Partnering and deal making 24 Selected acquisition by UK companies in 2016 24 Pipeline 28 The future 30 Updated 22 September 2017 Foreword from UK BioIndustry Association Chief Executive, Steve Bates, OBE The UK has some of the world’s most exciting science, a supportive business environment, and strong companies led by experienced management teams.
    [Show full text]
  • Annual Report 2012
    Registered office and Investor relations Registrar US Depositary 2012 20-F Information Form and Report Annual AstraZeneca AstraZeneca Annual Report corporate headquarters [email protected] Equiniti Limited JPMorgan Chase & Co and Form 20-F Information 2012 AstraZeneca PLC Aspect House PO Box 64504 2 Kingdom Street UK: as above Spencer Road St Paul London W2 6BD Lancing MN 55164-0504 UK US West Sussex BN99 6DA US Tel: +44 (0)20 7604 8000 Investor Relations UK Tel: (toll free in the US) Fax: +44 (0)20 7604 8151 AstraZeneca Pharmaceuticals LP Tel: (freephone in the UK) 888 697 8018 1800 Concord Pike 0800 389 1580 Tel: (outside the US) PO Box 15437 Tel: (outside the UK) +1 (651) 453 2128 Wilmington +44 (0)121 415 7033 [email protected] DE 19850-5437 US Swedish Central Securities Tel: +1 (302) 886 3000 Depository Fax: +1 (302) 886 2972 Euroclear Sweden AB PO Box 191 SE-101 23 Stockholm Sweden Tel: +46 (0)8 402 9000 Delivering value This Annual Report is also available on through innovation our website, astrazeneca.com/ annualreport2012 Important information for readers of this Annual Report AstraZeneca Cautionary statement regarding Innovation is at the core of everything we forward-looking statements Welcome to the AstraZeneca The purpose of this Annual Report is to provide Annual Report and Form information to the members of the Company. The do at AstraZeneca – from our research 20-F Information 2012 Company and its Directors, employees, agents and (Annual Report). You will find advisers do not accept or assume responsibility to into effective new medicines to how we this Annual Report on our any other person to whom this Annual Report is website, astrazeneca.com/ shown or into whose hands it may come and any annualreport2012 such responsibility or liability is expressly disclaimed.
    [Show full text]
  • UK Specialty Pharma Companies Outperform Biotech
    September 18, 2008 UK specialty pharma companies outperform biotech Amy Brown Shares in companies judged to be risky prospects have performed poorly this year, and the life sciences sector has been hit particularly badly by increasingly risk-averse investors. In particular, the fate of small biotechnology companies has not been pretty; even an absence of news, as opposed to actual clinical failure, has been enough to send share prices tumbling. Specialty pharma companies, however, have escaped such a severe mauling. This bodes well for BTG, which this morning announced the acquisition of fellow UK company Protherics, with the aim of giving its specialty pharma ambitions a boost. The table below shows the performance of UK listed biotechnology and specialty pharma companies. While both groups have declined, an investor more heavily exposed to the latter group will be doing considerably better. With their lower risk business model and a more realistic chance of achieving profitability, this is not too surprising. Specialty pharma will focus on later stage products, leaving the high risk R&D to someone else. This is exactly what BTG plans to do following the acquisition of Protherics. Over the next few months, the group will be culling early stage projects from the pipeline, while looking for niche, late stage products to acquire. Given the early stage of the deal, full plans have not yet been announced, but some commentators questioned the lack of a definite therapeutic focus emerging. If the deal proceeds, an update should be given alongside preliminary results in May, and investors will be looking out for a more defined strategy.
    [Show full text]